<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="760">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00166244</nctid>
  <trial_identification>
    <studytitle>Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation</studytitle>
    <scientifictitle>An Open, Prospective, Randomised, Controlled, Multi-Center Study Comparing Fixed Dose vs Concentration Controlled Mycophenolate Mofetil Regimens for de Novo Patients Following Transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FDCC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>De Novo Renal Transplant Recipient.</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Mycophenolate Mofetil

Active Comparator: Fixed Dose - 1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.

Active Comparator: Concentration Controlled - 1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.


Treatment: drugs: Mycophenolate Mofetil
1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.
Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment failure including the occurrence of the first one of any of the following: biopsy-proven acute rejection, graft loss, death or discontinuation of MMF therapy during the first 12 months following transplantation.</outcome>
      <timepoint>12 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients treated for acute rejection during the first 3, 6, 12 months post-transplantation,</outcome>
      <timepoint>3, 6 and 12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first acute rejection,</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of acute rejection episodes per patient in the first year post-transplantation,</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall treatment outcome at 12 months post-transplantation which is composed of any one of the following:</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Graft loss,</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death,</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Discontinuation of MMF therapy,</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient lost to follow-up.</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Renal transplant recipients who have completed their second birthday,

          -  Recipients from living (related or unrelated), cadaveric (non-heart beating or heart
             beating) donors,

          -  Single organ recipient (kidney only),

          -  Women of childbearing potential should have a negative serum or urine pregnancy test
             with a sensitivity of at least 50 mIU/ml within 1 week prior to beginning MMF
             treatment. Effective contraception must be used before beginning therapy, during
             therapy and for 6 weeks following discontinuation of therapy, even where there has
             been a history of infertility, unless due to hysterectomy,

          -  Patients or patient's parent/guardian providing written informed consent,

          -  Patients co-operative and able to complete all the assessment procedures.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients receiving immunosuppressive therapy (except steroid treatment) within the
             preceding 28 days, except that immunosuppressive medication may be initiated up to 48
             hours before transplantation. Furthermore, all patients should receive 1 g [adults] or
             600 mg/m2 [paediatric patients] of MMF therapy within 6 hours prior to
             transplantation,

          -  PRA &gt; 50% within 6 months prior to enrolment,

          -  Cold ischaemia time &gt;48 hours,

          -  History of malignancy (except localised non-melanotic skin cancer) or the presence of
             any active malignancy at the time of transplant,

          -  Active peptic ulcer disease,

          -  Active infection,

          -  Mandatory intake of prohibited drugs or it is probable that the patient will require
             treatment with such drugs after transplant,

          -  Pregnant or lactating females,

          -  Women of child-bearing potential not willing to use a reliable form of contraception,

          -  Patient is allergic or intolerant to polysorbate 80 (TWEEN), phenylalanine
             (aspartame), steroids, MMF, MPA, tacrolimus or cyclosporin,

          -  Patient or donor with positive tests for HIV or hepatitis B surface antigen,

          -  Patients with liver cirrhosis or clinical evidence of portal hypertension or other
             indication of moderate or severe liver disease. (Note: it is strongly recommended that
             patients with hepatitis C have a liver biopsy performed prior to transplantation),

          -  Incompatible ABO blood type and/or positive crossmatch,

          -  Patient has any form of substance abuse, psychiatric disorder or condition, which, in
             the opinion of the investigator, may invalidate communication with the investigator or
             with study procedures,

          -  Patients whose laboratory results reveal severe anaemia (as defined by a haemoglobin
             value &lt;6 mmol/L [9.7 g/dL] for adults receiving erythropoietin, &lt;4.1 mmol/L [6.6 g/dL]
             for paediatric patients [regardless of erythropoietin treatment]), leukopenia (as
             defined by a WBC value of &lt;2500/mm3) or thrombocytopenia (as defined by a platelet
             count of &lt;75,000/mm3).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>901</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2305 - New Lambton</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6847 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Sichuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Kremlin Bicêtre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Suresnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wurzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>07014</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badajoz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago De Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Venezuela</country>
      <state>Caracas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Venezuela</country>
      <state>Maracaibo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Erasmus Medical Center</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Hoffmann-La Roche</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared
      with fixed dosing in de novo MMF treated renal transplant recipients with respect to the
      incidence of treatment failure.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00166244</trialwebsite>
    <publication>van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999 Jul 27;68(2):261-6.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Teun van Gelder, Dr</name>
      <address>Erasmus Medical Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>